Table 2.
The univariate and multivariate analysis for progression free survival rate for high-grade serous carcinomas.
| Variables | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-valuea | ||
| Age | < 55/ ≥ 55 | 0.908 (0.461–1.788) | 0.780 | ||
| Family history of ovarian cancer | Absent/present | 0.892 (0.541–1.470) | 0.653 | ||
| Menopause | No/Yes | 1.029 (0.515–2.057) | 0.935 | ||
| Serum CA-125 | < 700/ ≥ 700 | 0.298 (0.726–2.841) | 0.298 | ||
| FIGO stage | 1–2/3/4 | 1.995 (1.127–3.532) | 0.018 | 1.913 (1.054–3.473) | 0.033 |
| Malignant ascites | Absent/present | 0.816 (0.427–1.559) | 0.538 | ||
| Residual tumor after operation | Absent/present | 2.271 (1.146–4.500) | 0.019 | 2.043 (1.010–4.129) | 0.047 |
| Germline BRCA1 or 2 mutations | Absent/present | 0.543 (0.267–1.1.5) | 0.092 | ||
| Platinum sensitivity | Sensitive/resistant | 2.149 (0.882–5.236) | 0.092 | ||
| Estrogen receptor | Negative/positive | 0.802 (0.391–1.645) | 0.547 | ||
| Stromal LGR5 | Low/high | 0.790 (0.367–1.703) | 0.548 | ||
| Epithelial LGR5 | Low/high | 0.456 (0.220–0.944) | 0.034 | 0.412 (0.198–0.856) | 0.018 |
HR Hazard ratio; CI confidence interval; FIGO International Federation of Gynecology and Obstetrics.
aCox proportional hazard model.